Roche’s Alzheimer’s therapy shows continued benefit
Roche’s therapy will be investigated in two Phase III studies due to begin by the end of 2025.
28 July 2025
28 July 2025
Roche’s therapy will be investigated in two Phase III studies due to begin by the end of 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.